MedTrace Logo

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

NCT06232460 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-09

No results posted yet for this study

Summary

This study evaluates the safety and tolerability of three different doses (5 g, 10 g and 20 g) of a collagen powder in healthy adults over a 12-week period.

Conditions

  • Tolerance

Interventions

DIETARY_SUPPLEMENT

H80

5g, 10g \& 20g

Sponsors & Collaborators

  • Rousselot BVBA

    lead INDUSTRY

Principal Investigators

  • Stacey Boetto, DNP, FNP-C · Atlantia Clinical Trials

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2024-07-29
Completion
2024-07-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232460 on ClinicalTrials.gov